Arkolith/Insider Trading/QNCX/Form 4

Hannah Brendan

CHIEF BUSINESS OFFICER AND COOQuince Therapeutics, Inc. (QNCX) · full profile →Form 4 · filed Jun 5, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 4, 2024Option exercise(M)56K$0.55$31K258K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 4, 2024Option exercise(M)56K—$047K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-015533) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML